RecruitingNCT06509230

Prediction of Significant Liver Fibrosis

Multimodal Digital Image Fusion Technology Based on Deep Learning to Predict Significant Liver Fibrosis and Its Application in Multi-center Research


Sponsor

Huang Haijun

Enrollment

700 participants

Start Date

Jul 20, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The deep learning method based on convolutional neural network (CNN) was used to extract the relevant features of liver fibrosis classification from the multi-modal information of digital pathological sections, clinical parameters and biomarkers of a large number of existing cases of liver puncture, and the U-Net architecture of CNN was used to segment and extract the features of clinical medical images.


Eligibility

Min Age: 18 YearsMax Age: 60 Years

Inclusion Criteria3

  • Age of 18-60 years old
  • The diagnosis of chronic hepatitis B is in line with the diagnostic criteria of China's 2019 Chronic Hepatitis B Prevention and Treatment Guidelines, and the diagnosis of non-alcoholic fatty liver is in line with the Asian Pacific Hepatology Association guidelines
  • Imaging showed no liver cancer

Exclusion Criteria2

  • There are contraindications for liver biopsy
  • Liver pathology did not meet the criteria

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHER

The fibrosis grades were grouped without drug intervention


Locations(1)

Haijun Huang

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06509230


Related Trials